Contineum Therapeutics (CTNM) Operating Expenses (2023 - 2026)

Contineum Therapeutics' Operating Expenses history runs 4 years deep, the most recent figure standing at $16.9 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 6.66% year-over-year to $16.9 million; the TTM figure through Mar 2026 stood at $66.9 million (up 13.17% YoY), while the FY2025 annual figure was $68.1 million, up 33.73% from the prior year.
• Operating Expenses was $16.9 million for Q1 2026 at Contineum Therapeutics, down from $17.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $18.1 million in Q1 2025 to a low of $5.1 million in Q1 2023.
• Historically, Operating Expenses has averaged $13.1 million across 4 years, with a median of $13.0 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Operating Expenses surged 94.13% in 2024, then fell 6.66% in 2026.
• A 4-year view of Operating Expenses shows it stood at $9.7 million in 2023, then jumped by 76.18% to $17.0 million in 2024, then climbed by 0.4% to $17.1 million in 2025, then fell by 1.23% to $16.9 million in 2026.
• The last three Operating Expenses figures came in at $16.9 million (Q1 2026), $17.1 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.